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IMPORTANCE Psoriasis is a chronic disease requiring long-term management; understanding
the long-term safety profiles of psoriasis treatments, such as bimekizumab, is important.
OBJECTIVE To evaluate the 2-year safety profile of bimekizumab in patients with moderate to

severe plaque psoriasis.
DESIGN, SETTING, AND PARTICIPANTS Safety data were pooled from a cohort of patients from
4 phase 2 randomized clinical trials (BE ABLE 1, BE ABLE 2, PS0016, and PS0018) and 4 phase
3 randomized clinical trials (BE VIVID, BE READY, BE SURE, and BE BRIGHT) to include 2 years
of study treatment. Data were obtained on adults with moderate to severe plaque psoriasis
(Psoriasis Area and Severity Index level ⱖ12, ⱖ10% body surface area affected by psoriasis,
and an Investigator’s Global Assessment score ⱖ3 on a 5-point scale) who were eligible for
systemic psoriasis therapy and/or phototherapy.
INTERVENTIONS Included patients received 1 or more doses of bimekizumab during the phase
2 or phase 3 trials.
MAIN OUTCOMES AND MEASURES Treatment-emergent adverse events (TEAEs), serious
TEAEs, and TEAEs leading to treatment discontinuation are reported using exposureadjusted incidence rates (EAIRs) per 100 person-years.
RESULTS A total of 1789 patients (1252 [70.0%] men; mean [SD] age, 45.2 [13.5] years) were
treated with 1 or more doses of bimekizumab across the phase 2/3 trials and were included in
these analyses; total bimekizumab exposure was 3109.7 person-years. TEAEs occurred at an
EAIR of 202.4 per 100 person-years and did not increase with longer duration of
bimekizumab exposure. The 3 most frequently reported TEAEs were nasopharyngitis (19.1
per 100 person-years; 95% CI, 17.4-20.9 per 100 person-years), oral candidiasis (12.6 per 100
person-years; 95% CI, 11.3-14.0 per 100 person-years), and upper respiratory tract infection
(8.9 per 100 person-years; 95% CI, 7.8-10.1 per 100 person-years). Most oral candidiasis
events were mild or moderate; 3 events led to discontinuation. The EAIRs of inflammatory
bowel disease (0.1 per 100 person-years; 95% CI, 0.0-0.3 per 100 person-years), adjudicated
suicidal ideation and behavior (0.0 per 100 person-years; 95% CI, 0.0-0.2 per 100
person-years), and adjudicated major adverse cardiac events (0.5 per 100 person-years; 95%
CI, 0.3-0.8 per 100 person-years) were low.
CONCLUSIONS AND RELEVANCE In these pooled analyses of data from a cohort of patients
from 8 randomized clinical trials, bimekizumab was well tolerated aside from an increased
incidence of mild to moderate oral candidiasis. No safety signals were observed compared
with previous reports, and there was no increased risk of AEs with longer duration of
bimekizumab exposure.
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T

he chronic nature of psoriasis can place a substantial
burden on patients’ health and quality of life.1-4 Longterm clinical trial data are valuable for evaluating the
safety profiles of psoriasis treatments.5 Biologic therapies
that inhibit key cytokines involved in psoriasis pathogenesis,
such as interleukin (IL)-23, tumor necrosis factor, and
IL-17A, are mainstays of treatment for patients with moderate to severe plaque psoriasis, and have well-established
safety profiles.6-13
Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both IL-17A and IL-17F.14-16 Bimekizumab has
previously demonstrated superior efficacy vs placebo,
ustekinumab (anti–IL-12/23), adalimumab (anti-tumor necrosis factor), and secukinumab (anti–IL-17A) for the treatment
of patients with moderate to severe plaque psoriasis.17-20
Safety data reported from the first year of clinical trials in
the bimekizumab treatment for plaque psoriasis clinical program demonstrated that bimekizumab is well tolerated, with
a safety profile in line with other anti–IL-17 biologics, aside from
an increased incidence of mild to moderate oral candidiasis,17-22
as a result of the protective roles of IL-17A and IL-17F against
fungal infections at the oral mucosa.20,23,24
We report safety data from 4 phase 2 randomized clinical
trials and 4 phase 3 randomized clinical trials in the bimekizumab plaque psoriasis clinical program, pooled to include 2
years of study treatment, to assess the longer-term safety profile of bimekizumab in patients with moderate to severe plaque
psoriasis.

Methods
Patient Population
Safety data were pooled from 4 phase 3 randomized clinical
trials (BE VIVID [NCT03370133], BE READY [NCT03410992],
BE SURE [NCT03412747], and BE BRIGHT [NCT03598790])17-19
and 4 phase 2 randomized clinic al trials (BE ABLE 1
[NCT02905006], BE ABLE 2 [NCT03010527], PS0016
[NCT03025542], and PS0018 [NCT03230292]).21,22,25,26 The
data cutoff for the ongoing BE BRIGHT trial was November 9,
2020; the last ongoing patient in BE BRIGHT reached 2 years
of study treatment on this date. All other trials included herein
were completed.
Full inclusion and exclusion c riteria have been
described.17-19,21,22,26 Eligible patients for all trials were adults
with moderate to severe plaque psoriasis, with a baseline Psoriasis Area and Severity Index (PASI) score greater than or equal
to 12, 10% or more of body surface area affected by psoriasis,
and an Investigator’s Global Assessment score greater than or
equal to 3 on a 5-point scale, who were eligible for systemic
psoriasis therapy and/or phototherapy. Patients with active
symptomatic inflammatory bowel disease (IBD), a recent (<6
months before screening) myocardial infarction or stroke, an
active tuberculosis (TB) infection, or a high risk of acquiring a
TB infection were excluded. For phase 2 trials, patients with
suicidal ideation less than 6 months before screening or a lifetime history of suicide attempts were excluded. For phase 3
trials, patients with active suicidal ideation less than 1 month
E2

JAMA Dermatology Published online May 11, 2022 (Reprinted)

Downloaded From: https://jamanetwork.com/ on 06/21/2022

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis

Key Points
Question What is the 2-year safety profile of bimekizumab in
patients with moderate to severe plaque psoriasis?
Findings In this cohort study including 1789 patients receiving
bimekizumab, pooled data on 2 years of study treatment from 4
phase 2 randomized clinical trials and 4 phase 3 randomized
clinical trials identified no safety signals. The incidence of adverse
events did not increase with longer duration of exposure to
bimekizumab.
Meaning These results, pooled to include 2 years of treatment,
suggest that bimekizumab is well tolerated among patients with
moderate to severe plaque psoriasis.

or a suicide attempt less than 5 years before screening were
excluded.

Study Designs
The trials were conducted in accordance with the principles
of the Declaration of Helsinki27 and approved by an independent review board and independent ethics committee. All participants provided informed written consent. Reporting in this
study followed the applicable portions of the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) reporting guideline.
Trials included in these analyses are summarized in
eTable 1 in the Supplement. Study designs for BE VIVID, BE
READY, and BE SURE were published previously.17-19 The BE
VIVID 52-week, randomized, double-blind, multicenter trial
randomized patients to bimekizumab, 320 mg, every 4 weeks
(Q4W), ustekinumab (per labeled dosing), or placebo to week
16 followed by bimekizumab, 320 mg, Q4W to week 52. The
BE READY 56-week, randomized withdrawal, double-blind,
multicenter trial randomized patients to bimekizumab, 320 mg,
Q4W or placebo to week 16. At week 16, bimekizumabtreated patients who achieved a 90% or greater reduction from
baseline in their PASI (PASI 90) score were rerandomized to
bimekizumab, 320 mg, Q4W, bimekizumab, 320 mg, every 8
weeks (Q8W), or placebo to week 56. Week 16 PASI 90 nonresponders entered a 12-week bimekizumab, 320 mg, Q4W openlabel escape group. The BE SURE 56-week, randomized,
double-blind, multicenter trial randomized patients to bimekizumab, 320 mg, Q4W, bimekizumab, 320 mg, Q4W to week
16 then Q8W to week 56, or adalimumab (per labeled dosing)
to week 24 followed by bimekizumab, 320 mg, Q4W to week
56. Patients completing each phase 3 trial were eligible to enroll in the BE BRIGHT open-label extension and received bimekizumab, 320 mg, Q4W or Q8W, depending on treatment,
dose, and PASI response on feeder trial completion.
Study designs for BE ABLE 1 and BE ABLE 2 phase 2b trials
have also been published.21,22 The 12-week BE ABLE 1 randomized, double-blind, dose-ranging trial randomized patients to
placebo or bimekizumab Q4W at doses of 64 mg, 160 mg,
160 mg with a 320-mg loading dose at baseline, 320 mg, or
480 mg. On BE ABLE 1 completion, patients could enroll in the
BE ABLE 2 48-week open-label extension. Treatment allocation in BE ABLE 2 depended on dosing in BE ABLE 1 and week
jamadermatology.com
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12 PASI response. PS0016 was a 28-week, phase 2a, randomized, double-blind, multicenter trial. Randomized patients received bimekizumab, 320 mg, at baseline and week 4 then placebo at week 16, or bimekizumab, 320 mg, at baseline, week
4, and week 16.26 On completion, eligible patients could enroll in the 48-week PS0018 open-label extension, in which patients received bimekizumab, 160 mg, Q4W and, at the investigators’ discretion, could increase the dose to 320 mg Q4W if
PASI 50 to less than PASI 75 was achieved at week 12 or later.

Safety Evaluations
Treatment-emergent adverse events (TEAEs), serious AEs, and
TEAEs leading to discontinuation are reported. TEAEs were defined as AEs that occurred during exposure to treatment including less than or equal to 140 days after the last dose. Serious AEs were defined as any AE that led to 1 or more of the
following: death, life-threatening event, substantial or persistent disability or incapacity, congenital anomaly or birth defect (including any occurring in a fetus), important medical
event, and initial or prolongation of hospitalization. TEAEs
were coded according to the Medical Dictionary for Regulatory Activities (MedDRA), version 19.0. The intensity of AEs
was assessed by the investigators as mild, moderate, or severe, independently from the seriousness.
Safety topics of interest were infections (serious, opportunistic, TB, and fungal), malignant neoplasms, major adverse cardiac events, neutropenia, suicidal ideation and behavior (SIB), IBD, hypersensitivity (including anaphylactic,
hypersensitivity, and injection site reactions), and elevated liver
enzyme/liver function test results.
Cardiovascular TEAEs were reviewed and adjudicated by
an independent cardiovascular clinical event adjudication committee. Predefined neuropsychiatric TEAEs and prespecified
questionnaire scores were assessed by an independent neuropsychiatric adjudication committee to determine events that
met SIB criteria. Assessments and monitoring of SIB were performed using the Columbia Suicide Severity Rating Scale.28
Opportunistic infections were predefined using company conventions. During the trials, patients were screened to
evaluate TB signs, symptoms, and possible exposure (eTable 2
in the Supplement). If a patient developed evidence of active
or latent TB, study treatment was stopped immediately and
patients would be referred to a TB specialist for further evaluation.

Statistical Analysis
Pooled safety data were assessed for all patients who
received 1 or more bimekizumab doses in the phase 2/3 trials
(phase 2/3 total) and in the phase 3 trials only (phase 3 total).
For patients who switched to bimekizumab from placebo,
ustekinumab, or adalimumab, only TEAEs that occurred
during exposure to bimekizumab are reported. Safety data
were also analyzed for patients who received bimekizumab,
320 mg, Q4W or Q8W in the phase 3 trials. TEAEs were
attributed to the dose most recently received before the
TEAE date of onset.
All TEAEs were evaluated based on exposure-adjusted
incidence rates (EAIRs), defined as the number of patients with
jamadermatology.com
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a specific AE adjusted for the duration of exposure. EAIRs are
reported per 100 person-years with associated 95% CIs. Data
analysis was conducted using SAS, version 9.4 (SAS Institute
LLC).

Results
Patient Population
Of the 1789 patients who received 1 or more doses of bimekizumab in the phase 2/3 trials (eFigure in the Supplement), 1252
were men (70.0%) and 537 were women (30.0%); mean (SD)
age was 45.2 (13.5) years. Baseline demographic and other characteristics were similar between bimekizumab dose groups and
were representative of patients with plaque psoriasis eligible
for biologic therapy (eTable 3 in the Supplement).
In total, 1789 patients received 1 or more doses of bimekizumab across the phase 2/3 trials (eFigure in the Supplement); total bimekizumab exposure was 3109.7 person-years
and median bimekizumab duration was 673.0 days (range,
1-1037). Of these patients, 1495 were treated with 1 or more
doses of bimekizumab in the phase 3 trials; total bimekizumab exposure was 2740.8 person-years and median bimekizumab duration was 730.0 days (range, 23-1037) (Table 1).

Overall Safety
TEAEs occurred at an EAIR of 202.4 per 100 person-years in
the phase 2/3 trials (Table 1) and did not increase with longer
duration of bimekizumab exposure (weeks 0-16: 324.7 per 100
person-years; 95% CI, 305.6-344.7 per 100 person-years; weeks
16-52: 225.5 per 100 person-years; 95% CI, 212.8-238.7 per 100
person-years; weeks 52-104: 149.1 per 100 person-years; 95%
CI, 139.4-159.3 per 100 person-years) (Figure 1A). In the phase
3 trials, the overall EAIR of TEAEs was lower in patients treated
with bimekizumab, 320 mg, Q8W (141.4 per 100 personyears; 95% CI, 129.6-153.9 per 100 person-years) than with bimekizumab, 320 mg, Q4W (219.6 per 100 person-years; 95%
CI, 207.3-232.3 per 100 person-years) (Table 1).
In the phase 2/3 trials, serious TEAEs occurred at a rate of
5.9 per 100 person-years (95% CI, 5.1-6.9 per 100 personyears) and EAIRs were consistent throughout the observed
treatment period (weeks 0-16: 6.1 per 100 person-years; 95%
CI, 4.2-8.6 per 100 person-years; weeks 16-52: 6.8 per 100 person-years; 95% CI, 5.3-8.6 per 100 person-years; weeks 52104: 5.6 per 100 person-years; 95% CI, 4.3-7.1 per 100 personyears) (Figure 1B). The EAIR of discontinuations due to a TEAE
was 3.8 per 100 person-years and was lower during the second year of treatment compared with the first. EAIRs decreased over the observed treatment period (weeks 0-16: 6.9
per 100 person-years; 95% CI, 4.8-9.5 per 100 person-years;
weeks 16-52: 4.9 per 100 person-years; 95% CI, 3.6-6.4 per 100
person-years; weeks 52-104: 2.1 per 100 person-years; 95% CI,
1.4-3.1 per 100 person-years). (Figure 1C). Most TEAEs were mild
or moderate; severe TEAEs occurred at a rate of 5.4 per 100
person-years. The EAIRs of severe TEAEs did not increase with
longer duration of bimekizumab exposure (weeks 0-16: 6.3 per
100 person-years; 95% CI, 4.4-8.8 per 100 person-years; weeks
16-52: 6.6 per 100 person-years; 95% CI, 5.2-8.4 per 100 person(Reprinted) JAMA Dermatology Published online May 11, 2022
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Table 1. Summary of Treatment Exposure and TEAEs in Bimekizumab-Treated Patients in the Phase 2 and Phase 3 Trialsa
EAIR per 100 person-years (95% CI)
Phase 3 (wk 0-16)b

Variable
Total exposure,
person-years

Phase 3

Placebo
(n = 169)

Bimekizumab,
320 mg, Q4W
(n = 670)

Bimekizumab,
320 mg, Q4W
(n = 1456)

Bimekizumab,
320 mg, Q8W
(n = 930)

Bimekizumab,
total
(n = 1495)

Phase 2/3,
bimekizumab,
total
(n = 1789)

51.6

207.7

1863.6

879.8

2740.8

3109.7

Exposure, d
Mean (SD)

107.4 (16.8)

110.6 (7.3)

456.3 (262.5)

342.2 (236.1)

659.0 (213.6)

608.5 (232.6)

Median (range)

112.0
(28-120)

112.0
(28-122)

455.5
(23-1037)

293.0
(1-869)

730.0
(23-1037)

673.0
(1-1037)

205.0
(161.0-257.4)

305.8
(276.4-337.6)

219.6
(207.3-232.3)

141.4
(129.6-153.9)

192.7
(182.5-203.3)

202.4
(192.6-212.6)

Any TEAE
Severe TEAEs

7.8 (2.1-19.9)

3.9 (1.7-7.6)

5.3 (4.3-6.5)

4.8 (3.4-6.5)

5.0 (4.2-5.9)

5.4 (4.6-6.3)

TEAEs leading to
discontinuation

13.8
(5.6-28.5)

5.3
(2.7-9.5)

3.6
(2.8-4.5)

2.7
(1.8-4.1)

3.3
(2.7-4.1)

3.8
(3.1-4.6)

Treatment-related
TEAEsc

30.7
(17.2-50.7)

80.0
(67.5-94.2)

43.4
(39.8-47.1)

28.9
(25.0-33.2)

35.5
(32.8-38.3)

35.4
(32.9-38.0)

Serious TEAEs

7.8 (2.1-20.0)

5.3 (2.7-9.5)

6.2 (5.1-7.4)

5.3 (3.8-7.0)

5.9 (5.0-6.9)

5.9 (5.1-6.9)

TEAEs leading
to death

1.9 (0.0-10.8)

0.5 (0.0-2.7)

0.3 (0.1-0.7)

0.3 (0.1-1.0)

0.3 (0.2-0.6)

0.4 (0.2-0.6)

groups exceeds the total number of patients in the bimekizumab total groups.
The data cutoff for the ongoing BE BRIGHT trial was November 9, 2020.

Abbreviations: EAIR, exposure-adjusted incidence rate; Q4W, every 4 weeks;
Q8W, every 8 weeks; TEAE, treatment-emergent adverse event.
a

For patients who received both Q4W and Q8W bimekizumab doses during the
trials, TEAEs were assigned to the dose most recently received before the date
of onset of the TEAE. Patients who received both bimekizumab, 320 mg, Q4W
and Q8W at different times in the trials are included in the total population
count of each treatment group, but only once in each bimekizumab total
group. Therefore, the total number of patients in both the Q4W and Q8W

b

Data are reported for events that occurred during the initial 16-week
treatment period of the BE VIVID and BE READY placebo-controlled phase 3
randomized clinical trials, using a different pool of patients to the longer-term
analyses.

c

Assessed by the investigators as related to treatment.

Figure 1. Incidence Rates of Treatment-Emergent Adverse Events (TEAEs) by Treatment Period
Bimekizumab phase 2/3 total (n = 1789)

Bimekizumab phase 2/3 total (n = 1599)

A TEAEs overall

B
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6
4
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Data are reported as the
exposure-adjusted incidence rate
(EAIR) per 100 person-years for
TEAEs that occurred during the initial
16-week treatment period of the
phase 2/3 trials (weeks 0-16), during
the maintenance period (weeks
16-52) and during the second year
(weeks 52-104). Error bars represent
95% CIs.

jamadermatology.com

Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis

Original Investigation Research

Table 2. Incidence Rates of TEAEs of Interesta
EAIR per 100 person-years (95% CI)
Phase 3
Bimekizumab,
320 mg Q8W
(n = 930)

Bimekizumab,
total
(n = 1495)

Phase 2/3,
bimekizumab,
total
(n = 1789)
1.0 (0.7-1.4)

Variable

Bimekizumab,
320 mg Q4W
(n = 1456)

Serious infections

1.4 (0.9-2.1)

0.3 (0.1-1.0)

1.1 (0.7-1.5)

Active tuberculosis

0

0

0

0

Fungal infections

25.7 (23.2-28.4)

16.5 (13.8-19.7)

20.7 (18.9-22.8)

20.1 (18.4-22.0)

Candida infections

18.9 (16.8-21.1)

10.6 (8.5-13.1)

14.6 (13.1-16.3)

14.2 (12.8-15.7)

Oral candidiasis

16.4 (14.5-18.5)

9.6 (7.6-12.0)

12.9 (11.5-14.4)

12.6 (11.3-14.0)

Oropharyngeal candidiasis

1.1 (0.7-1.7)

0.3 (0.1-1.0)

0.9 (0.6-1.3)

0.8 (0.6-1.2)

Skin candidiasis

0.7 (0.4-1.2)

0.8 (0.3-1.6)

0.7 (0.4-1.1)

0.7 (0.4-1.0)

Vulvovaginal candidiasis

0.8 (0.5-1.3)

0

0.6 (0.3-0.9)

0.6 (0.3-0.9)

Esophageal candidiasis

0.2 (0.1-0.6)

0.1 (0.0-0.6)

0.2 (0.1-0.4)

0.2 (0.1-0.4)

Tinea infections

3.0 (2.3-4.0)

2.9 (1.9-4.3)

2.8 (2.2-3.5)

2.7 (2.1-3.3)

Fungal infections NECb

3.8 (2.9-4.8)

2.3 (1.4-3.6)

3.1 (2.5-3.9)

3.1 (2.5-3.7)

Inflammatory bowel disease

0.2 (0.0-0.5)

0.1 (0.0-0.6)

0.1 (0.0-0.4)

0.1 (0.0-0.3)

Adjudicated MACE

0.5 (0.3-1.0)

0.3 (0.1-1.0)

0.5 (0.3-0.8)

0.5 (0.3-0.8)

Malignant neoplasms

0.6 (0.3-1.1)

0.9 (0.4-1.8)

0.7 (0.4-1.1)

0.8 (0.5-1.2)

Excluding NMSC

0.3 (0.1-0.7)

0.7 (0.3-1.5)

0.4 (0.2-0.8)

0.5 (0.2-0.8)

NMSC

0.3 (0.1-0.7)

0.2 (0.0-0.8)

0.3 (0.1-0.6)

0.3 (0.2-0.6)

Adjudicated SIB

0.1 (0.0-0.3)

0

0.0 (0.0-0.2)

0.0 (0.0-0.2)

Neutropenia

0.8 (0.5-1.3)

0.2 (0.0-0.8)

0.6 (0.3-1.0)

0.8 (0.6-1.2)

Hepatic events

3.7 (2.9-4.7)

2.9 (1.9-4.3)

3.2 (2.6-4.0)

4.3 (3.6-5.2)

Elevated liver enzyme levelsc

3.1 (2.4-4.1)

2.2 (1.3-3.4)

2.6 (2.0-3.3)

3.6 (3.0-4.4)

Serious hypersensitivity reactionsd

0.2 (0.0-0.5)

0.1 (0.0-0.6)

0.1 (0.0-0.4)

0.2 (0.1-0.4)

Injection site reactions

2.7 (2.0-3.6)

1.7 (1.0-2.9)

2.3 (1.8-2.9)

2.3 (1.8-2.9)

Abbreviations: EAIR, exposure-adjusted incidence rate; MACE, major adverse
cardiac event; NEC, not elsewhere classified; NMSC, nonmelanoma skin cancer;
Q4W, every 4 weeks; Q8W, every 8 weeks; SIB, suicidal ideation and behavior;
TEAE, treatment-emergent adverse event.

b

Includes oral fungal infection, skin fungal infection, vulvovaginal mycotic
infection, onychomycosis, tongue fungal infection, fungal infection, fungal
pharyngitis, genital fungal infection, fungal oropharyngitis, anal fungal
infection, ear fungal infection, and fungal esophagitis.

a

c

Liver function tests included the following preferred terms reported as
adverse events: increased hepatic enzyme, aspartate aminotransferase,
γ-glutamyl transferase, alanine aminotransferase, liver function test,
transaminases, blood bilirubin, and abnormal liver function test.

d

There were no incidences of acute anaphylactic reactions associated with
bimekizumab.

For patients who received both Q4W and Q8W bimekizumab doses during the
trials, TEAEs were assigned to the dose most recently received before the date
of onset of the TEAE. Patients who received both bimekizumab, 320 mg, Q4W
and Q8W at different times in the trials are included in the total population
count of each treatment group, but only once in each bimekizumab total
group. Therefore, the total number of patients in both the Q4W and Q8W
groups exceeds the total number of patients in the bimekizumab total groups.
The data cutoff for the ongoing BE BRIGHT trial was November 9, 2020.

years; weeks 52-104: 5.5 per 100 person-years; 95% CI, 4.27.0 per 100 person-years) (Figure 1D). The most frequently reported TEAEs by MedDRA-preferred term were nasopharyngitis
(19.1 per 100 person-years; 95% CI, 17.4-20.9), oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0), and upper
respiratory tract infection (8.9 per 100 person-years; 95% CI,
7.8-10.1) (eTable 4 in the Supplement).

Deaths
In total, 11 deaths (0.4 per 100 person-years) were reported for
patients receiving bimekizumab in the phase 2/3 trials (Table 1).
Causes of death were reported under the following MedDRApreferred terms, each for 1 patient, unless otherwise specified: cardiopulmonary failure, myocardial infarction, cardiac
arrest (3 patients), death (unknown cause, 3 months after last
bimekizumab dose), brain neoplasm, completed suicide, dyspnea, chronic obstructive pulmonary disease, circulatory
jamadermatology.com
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collapse (2 patients), respiratory failure, and hypovolemic
shock. No deaths were assessed by the investigators as
related to treatment.

Infections
The EAIR of infections was 96.7 per 100 person-years. The EAIR
of serious infections was low (phase 2/3 trials: 1.0 per 100 person-years; 95% CI, 0.7-1.4 per 100 person-years), and in the
phase 3 trials was lower with bimekizumab, 320 mg, Q8W (0.3
per 100 person-years; 95% CI, 0.1-1.0 per 100 person-years)
compared with Q4W (1.4 per 100 person-years; 95% CI, 0.92.1 per 100 person-years) (Table 2). The incidence of serious
infections did not increase with a longer duration of bimekizumab exposure (weeks 0-16: 1.0 per 100 person-years; 95%
CI, 0.2-2.9 per 100 person-years; 1 year: 1.4 per 100 personyears; 95% CI, 0.9-2.0 per 100 person-years; 2 years: 1.0 per
100 person-years; 95% CI, 0.7-1.4 per 100 person-years)
(Reprinted) JAMA Dermatology Published online May 11, 2022
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Figure 2. Cumulative Incidence Rates for Selected Treatment-Emergent Adverse Events (TEAEs) of Interest
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assigned to bimekizumab received bimekizumab, 320 mg, every 4 weeks
(Q4W). Longer-term data through to 1 year (clinical cutoff date November 1,
2019) and 2 years (clinical cutoff date November 9, 2020) of bimekizumab
treatment were pooled from 4 phase 2 and 4 phase 3 randomized clinical trials.
Error bars represent 95% CIs.

(Figure 2A). The most common serious infection was cellulitis (4 events). No cases of active TB were reported (Table 2).
The overall EAIR of opportunistic infections was 1.2 per
100 person-years (95% CI, 0.9-1.7). Almost all opportunistic infections reported with bimekizumab were localized mucocutaneous fungal infections predefined as opportunistic by company convention, except for 1 serious case of ophthalmic herpes
zoster that resolved with treatment and did not lead to discontinuation.
Fungal infections occurred at a rate of 20.1 per 100 personyears (95% CI, 18.4-22.0) (phase 2/3). Most were Candida infections (14.2 per 100 person-years; 95% CI, 12.8-15.7 per 100
person-years); EAIRs for other fungal infections, including
Tinea infections, were low (Table 2).

cumulative EAIR of oral candidiasis decreased with a longer
duration of bimekizumab exposure as shown in Figure 2B
(weeks 0-16: 25.3 per 100 person-years; 95% CI, 19.9-31.8 per
100 person-years; 1 year: 16.4 per 100 person-years; 95% CI,
14.5-18.5 per 100 person-years; 2 year: 12.6 per 100 personyears; 95% CI, 11.3-14.0 per 100 person-years). In the phase 2/3
trials, the incidence of oral candidiasis decreased by treatment period as shown in Figure 3A (weeks 0-16: 24.7 per 100
person-years; 95% CI, 20.6-29.3 per 100 person-years; weeks
16-52: 18.9 per 100 person-years; 95% CI, 16.3-21.8 per 100 person-years; weeks 52-104: 12.3 per 100 person-years; 95% CI,
10.3-14.6 per 100 person-years). Most oral candidiasis events
were mild or moderate in severity, 5 were reported as severe
(0.2 per 100 person-years; 95% CI, 0.1-0.4), and none were reported as serious.
In the phase 3 trials, the EAIR of oral candidiasis was lower
for patients who received bimekizumab, 320 mg, Q8W (9.6 per
100 person-years; 95% CI, 7.6-12.0 per 100 person-years) vs bimekizumab, 320 mg, Q4W (16.4 per 100 person-years; 95% CI,
14.5-18.5 per 100 person-years) (Table 2). In BE SURE and BE
READY, in which both bimekizumab Q4W and Q8W mainte-

Candidiasis
Candida infections were predominantly reported as oral candidiasis (12.6 per 100 person-years; 95% CI, 11.3-14.0 per 100
person-years) (Table 2). Of the patients in the phase 2/3 trials,
275 of 1789 (15.4%) reported an oral candidiasis event in the
first year and 131 of 1435 (9.1%) during the second year. The
E6
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Figure 3. Incidence and Recurrence of Oral Candidiasis Treatment-Emergent Adverse Events (TEAEs)
Over 1 and 2 Years
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nance dosing regimens were possible, the EAIR of oral candidiasis was lower in the second year compared with the first for
patients who received either bimekizumab Q4W or Q8W continuous maintenance dosing. In addition, the EAIR of oral candidiasis was lower in each period for patients who received continuous Q8W bimekizumab maintenance dosing compared
with continuous Q4W maintenance dosing (weeks 16-52, Q8W:
18.6 per 100 person-years; 95% CI, 12.0-27.5 per 100 personyears; Q4W: 24.6 per 100 person-years; 95% CI, 14.1-40.0 per
100 person-years; weeks 52-104, Q8W: 10.6 per 100 personyears; 95% CI, 6.4-16.5 per 100 person-years; Q4W: 13.0 per
100 person-years; 95% CI, 6.2-23.8 per 100 person-years)
(Figure 3B).
Over 2 years of treatment, 170 patients (9.5%) reported 1
incidence of oral candidiasis, 88 (4.9%) reported 2 incidences, 33 (1.8%) reported 3 incidences, 22 (1.2%) reported 4
incidences, and 20 (1.1%) reported 5 or more incidences
(Figure 3D). The method of oral candidiasis treatment was at
the discretion of the investigators and most patients with oral
candidiasis were treated with nystatin and/or fluconazole. The
median treatment duration with antifungal therapies was 12.0
days (IQR, 7.0-22.0 days). Most events were resolved with treatment; 3 patients (0.2%) with oral candidiasis discontinued bimekizumab.
In the phase 2/3 trials, 2 patients (0.1%) with esophageal
candidiasis, 1 (<0.1%) with oropharyngeal candidiasis, and
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doses of bimekizumab at week 16 or
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bimekizumab maintenance dosing
(every 4 weeks [Q4W] or every 8
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maintenance periods of the BE
READY and BE SURE phase 3 studies
and the BE BRIGHT open-label
extension. All patients received
bimekizumab, 320 mg, Q4W during
the initial 16-week period of BE
READY and BE SURE. C, Data are
reported to 1 year and 2 years of
treatment for all patients in the phase
2/3 trials who received 1 or more
doses of bimekizumab. Error bars
represent 95% CIs.

1 (<0.1%) with skin Candida discontinued bimekizumab treatment. Of these, 1 patient receiving bimekizumab, 320 mg, Q4W
reported a serious, severe case of esophageal candidiasis; this
patient was hospitalized, received antifungal therapy, and the
infection resolved after 14 days. No other serious Candida infections were reported.

Inflammatory Bowel Disease
The EAIR of IBD was low (0.1 per 100 person-years; 95% CI,
0.0-0.3 per 100 person-years) and did not increase with longer duration of bimekizumab exposure (weeks 0-16: 0.3 per
100 person-years; 95% CI, 0.0-1.8 per 100 person-years; 1 year:
0.1; 95% CI, 0.0-0.3 per 100 person-years; 2 years: 0.1 per 100
person-years; 95% CI, 0.0-0.3 per 100 person-years)
(Figure 2C). In total, 4 cases were reported (2 Crohn disease, 1
colitis, and 1 ulcerative colitis); all occurred in the phase 3 trials
(Table 2). Three cases of IBD led to discontinuation of treatment, 2 of which were considered by the investigators to be
related to treatment.

Malignant Neoplasms
In the phase 2/3 trials, excluding nonmelanoma skin cancer,
there were 14 incidences of cancer (0.5 per 100 person-years;
95% CI, 0.2-0.8 per 100 person-years) (Table 2); the EAIR remained low with a longer duration of bimekizumab exposure
(Figure 2D). Overall, including nonmelanoma skin cancer, 26
(Reprinted) JAMA Dermatology Published online May 11, 2022
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cancers were reported in 24 patients (0.8 per 100 per 100
person-years; 95% CI, 0.5-1.2 per 100 person-years) (Table 2).
No incidences of cancer were assessed by the investigators as
related to treatment.

Other TEAEs of Interest
The EAIR of adjudicated major adverse cardiac events in the
phase 2/3 trials was 0.5 per 100 person-years (95% CI, 0.3-0.8
per 100 person-years) (Table 2) and did not increase with a longer duration of bimekizumab exposure (Figure 2E). The EAIR
of neutropenia was 0.8 per 100 person-years (95% CI, 0.6-1.2
per 100 person-years) (Table 2); most cases were mild or moderate and 2 led to discontinuation of treatment. The EAIR of
serious hypersensitivity reactions was low (0.2 per 100 personyears; 95% CI, 0.1-0.4 per 100 person-years) (Table 2). Injection site reactions occurred at an EAIR of 2.3 per 100 personyears (95% CI, 1.8-2.9 per 100 person-years); all cases were mild
or moderate and none led to discontinuation. Hepatic events
occurred at an EAIR of 4.3 per 100 person-years (95% CI, 3.65.2 per 100 person-years) and were predominantly reports of
increased liver enzyme levels (Table 2). The increased liver enzyme levels observed mostly had alternative causes and were
reversed with either continued treatment or shortly after discontinuation, such that bimekizumab was still at therapeutic
levels.
Overall, the incidence of adjudicated SIB was low (0.0 per
100 person-years; 95% CI, 0.0-0.2 per 100 person-years)
(Table 2; Figure 2F); 1 patient receiving bimekizumab, 320 mg,
Q4W recorded a positive electronic Columbia Suicide Severity Rating Scale response to question 4 (active suicidal ideation with some intent to act), which was adjudicated as SIB
and led to discontinuation of treatment. One event of completed suicide in a patient receiving bimekizumab was adjudicated as SIB after the data cutoff for these analyses and therefore is not included in the EAIR of SIB reported herein. The
patient had no known psychiatric medical history, but financial issues were reported as risk factors; the event was assessed by the investigators as not related to treatment.

Discussion
In these analyses, data were pooled to include 2 years of study
treatment for patients with moderate to severe plaque psoriasis who received bimekizumab across 4 phase 2 randomized
clinical trials and 4 phase 3 randomized clinical trials. Overall, the incidence of TEAEs decreased with a longer duration
of bimekizumab exposure. In the phase 3 trials, the incidence
of TEAEs was lower in patients treated with bimekizumab,
320 mg, Q8W compared with Q4W. The rate of discontinuation due to TEAEs was low.
Nasopharyngitis, oral candidiasis, and upper respiratory
tract infection were the most common TEAEs reported with
bimekizumab. The risk of infections for patients with psoriasis is higher than in the general population, and anti–IL-17 biologics may increase this risk.4,29,30 In addition, the use of biologic and systemic treatments for psoriasis may increase the
risk of serious infections.31 In these analyses, the EAIR of
E8
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serious infections was low (1.0 per 100 person-years), did not
increase with longer exposure to bimekizumab, and was comparable with the estimated rate among patients with psoriasis in the Psoriasis Longitudinal Assessment and Registry (1.6
per 100 person-years),32 and EAIRs reported in clinical studies with other IL-17 inhibitors (secukinumab: 1.4 per 100
person-years10,33; brodalumab: 1.0-1.3 per 100 person-years13;
and ixekizumab: 1.3-2.3 per 100 person-years).8,12,34
Interleukin-17 is involved in mucosal host defenses against
fungal infections; therefore, anti–IL-17 biologics can be associated with an increased risk of oral mucocutaneous
candidiasis.35-39 Consistent with individual study data,17-22 oral
candidiasis was one of the most common TEAEs reported with
bimekizumab (12.6 per 100 person-years), and the EAIR was
higher than that reported in pooled studies up to 5 years with
other IL-17 inhibitors (secukinumab: 1.9 per 100 person-years33;
ixekizumab: 0.8-1.2 per 100 person-years).12,34 In these pooled
data, most oral candidiasis events with bimekizumab were mild
to moderate in intensity, and the rate of discontinuation due
to oral candidiasis was low (0.2%). The EAIR of oral candidiasis decreased with a longer duration of bimekizumab exposure and was lower with bimekizumab Q8W compared with
Q4W. The EAIRs of other fungal infections were low.
Patients with psoriasis can be at increased risk of IBD.40-42
In addition, rare exacerbations of IBD have been reported with
inhibitors of IL-17A.43,44 In the phase 2/3 trials, the incidence
of IBD with bimekizumab was low (0.1 per 100 person-years)
and similar to rates reported in a psoriasis cohort study (Crohn
disease: 0.03 per 100 person-years; ulcerative colitis: 0.07 per
100 person-years),42 and other long-term anti–IL-17 clinical
studies (secukinumab: 0.01-0.3 per 100 person-years10,33; ixekizumab: 0.2 per 100 person-years).12 Cases of IBD in these
pooled analyses were mild or moderate, 3 led to discontinuation, and 2 were assessed by the investigators as related to treatment. Inflammatory bowel disease events were not adjudicated for these analyses and, owing to the low incidence, it was
not possible to identify specific characteristics that may have
predisposed patients to develop IBD.
Psoriasis can place a substantial burden on patient quality of life, and patients may be at increased risk of depression
and SIB.24,45 In these analyses, the incidence of adjudicated
SIB was low and within the background rate for patients with
psoriasis.46

Limitations
This study has limitations. Although these analyses report
safety data for a large population of patients who received bimekizumab, the data may not fully represent a real-world
population owing to the specific patient inclusion and exclusion criteria of the trials analyzed. Furthermore, the population may be too small to draw definitive conclusions for more
rare events.

Conclusions
In these analyses pooled to include 2 years of treatment in a
cohort of patients from 8 randomized clinical trials, bimekijamadermatology.com
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zumab demonstrated a favorable safety profile and no safety
signals were observed. In the phase 3 trials, the incidence of
AEs was lower with bimekizumab, 320 mg, Q8W compared
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